The randomized 2x2x2 factorial design placebo controlled trial will enroll 5000 participants
(women 60 years or older and men 55 years or older) without known heart disease or prior
stroke and without a clear indication or contraindication to any of the study medications.
Eligible and consenting individuals will be randomized to receive either the active study
medications or placebo (dummy pills) and will be monitored for an average of 5 years. The
study will include people from at 10 countries, will be conducted by an international group
of scientists and physicians and will be coordinated by the Population Health Research
Institute at Hamilton Health Sciences.
Phase:
Phase 3
Details
Lead Sponsor:
Population Health Research Institute
Collaborators:
Cadila Pharnmaceuticals Canadian Institutes of Health Research (CIHR) Heart and Stroke Foundation of Ontario Wellcome Trust
Treatments:
Aspirin Cholecalciferol Ergocalciferols Vitamin D Vitamins